154 related articles for article (PubMed ID: 34924133)
1. Dihydroartemisinin enhances the inhibitory effect of sorafenib on HepG2 cells by inducing ferroptosis and inhibiting energy metabolism.
Cui Z; Wang H; Li S; Qin T; Shi H; Ma J; Li L; Yu G; Jiang T; Li C
J Pharmacol Sci; 2022 Jan; 148(1):73-85. PubMed ID: 34924133
[TBL] [Abstract][Full Text] [Related]
2. Dihydroartemisinin induces ferroptosis of hepatocellular carcinoma via inhibiting ATF4-xCT pathway.
Ji J; Cheng Z; Zhang J; Wu J; Xu X; Guo C; Feng J
J Cell Mol Med; 2024 Apr; 28(8):e18335. PubMed ID: 38652216
[TBL] [Abstract][Full Text] [Related]
3. Protein phosphatase 2A-B55β mediated mitochondrial p-GPX4 dephosphorylation promoted sorafenib-induced ferroptosis in hepatocellular carcinoma via regulating p53 retrograde signaling.
Qian B; Che L; Du ZB; Guo NJ; Wu XM; Yang L; Zheng ZX; Gao YL; Wang MZ; Chen XX; Xu L; Zhou ZJ; Lin YC; Lin ZN
Theranostics; 2023; 13(12):4288-4302. PubMed ID: 37554285
[No Abstract] [Full Text] [Related]
4. A Photoactivated Sorafenib-Ruthenium(II) Prodrug for Resistant Hepatocellular Carcinoma Therapy through Ferroptosis and Purine Metabolism Disruption.
Lai Y; Lu N; Luo S; Wang H; Zhang P
J Med Chem; 2022 Oct; 65(19):13041-13051. PubMed ID: 36134739
[TBL] [Abstract][Full Text] [Related]
5. DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism.
Du J; Wang X; Li Y; Ren X; Zhou Y; Hu W; Zhou C; Jing Q; Yang C; Wang L; Li H; Fang L; Zhou Y; Tong X; Wang Y
Cell Death Dis; 2021 Jul; 12(7):705. PubMed ID: 34262021
[TBL] [Abstract][Full Text] [Related]
6. Preparation and characterization of parthenolide nanocrystals for enhancing therapeutic effects of sorafenib against advanced hepatocellular carcinoma.
Liang P; Wu H; Zhang Z; Jiang S; Lv H
Int J Pharm; 2020 Jun; 583():119375. PubMed ID: 32344021
[TBL] [Abstract][Full Text] [Related]
7. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma.
Li ZJ; Dai HQ; Huang XW; Feng J; Deng JH; Wang ZX; Yang XM; Liu YJ; Wu Y; Chen PH; Shi H; Wang JG; Zhou J; Lu GD
Acta Pharmacol Sin; 2021 Feb; 42(2):301-310. PubMed ID: 32699265
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis.
Feng J; Dai W; Mao Y; Wu L; Li J; Chen K; Yu Q; Kong R; Li S; Zhang J; Ji J; Wu J; Mo W; Xu X; Guo C
J Exp Clin Cancer Res; 2020 Jan; 39(1):24. PubMed ID: 32000827
[TBL] [Abstract][Full Text] [Related]
9. Ferroptosis triggered by dihydroartemisinin facilitates chlorin e6 induced photodynamic therapy against lung cancerthrough inhibiting GPX4 and enhancing ROS.
Han N; Li LG; Peng XC; Ma QL; Yang ZY; Wang XY; Li J; Li QR; Yu TT; Xu HZ; Xu X; Chen X; Wang MF; Li TF
Eur J Pharmacol; 2022 Mar; 919():174797. PubMed ID: 35122867
[TBL] [Abstract][Full Text] [Related]
10. DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin.
Du J; Wang T; Li Y; Zhou Y; Wang X; Yu X; Ren X; An Y; Wu Y; Sun W; Fan W; Zhu Q; Wang Y; Tong X
Free Radic Biol Med; 2019 Feb; 131():356-369. PubMed ID: 30557609
[TBL] [Abstract][Full Text] [Related]
11. Ferroptosis plays an essential role in the antimalarial mechanism of low-dose dihydroartemisinin.
Li S; Xu W; Wang H; Tang T; Ma J; Cui Z; Shi H; Qin T; Zhou H; Li L; Jiang T; Li C
Biomed Pharmacother; 2022 Apr; 148():112742. PubMed ID: 35228063
[TBL] [Abstract][Full Text] [Related]
12. Dihydroartemisinin triggers ferroptosis in primary liver cancer cells by promoting and unfolded protein response‑induced upregulation of CHAC1 expression.
Wang Z; Li M; Liu Y; Qiao Z; Bai T; Yang L; Liu B
Oncol Rep; 2021 Nov; 46(5):. PubMed ID: 34558645
[TBL] [Abstract][Full Text] [Related]
13. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma.
Hua HW; Jiang HS; Jia L; Jia YP; Yao YL; Chen YW; Jiang F; Lu DQ; Zhou Q; Jiang MW; Ding G
Cancer Biomark; 2021; 32(4):425-433. PubMed ID: 33843664
[TBL] [Abstract][Full Text] [Related]
14. Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of sorafenib and Dihydroartemisinin in liver cancers.
Wang Z; Duan X; Lv Y; Zhao Y
Life Sci; 2019 Dec; 239():117013. PubMed ID: 31678287
[TBL] [Abstract][Full Text] [Related]
15. Dual GSH-exhausting sorafenib loaded manganese-silica nanodrugs for inducing the ferroptosis of hepatocellular carcinoma cells.
Tang H; Chen D; Li C; Zheng C; Wu X; Zhang Y; Song Q; Fei W
Int J Pharm; 2019 Dec; 572():118782. PubMed ID: 31678528
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Apoc1 reverses resistance of sorafenib by promoting ferroptosis in esophageal cancers.
Hu J; Hu H; Liu Q; Feng B; Lu Y; Chen K
Gene; 2024 Jan; 892():147874. PubMed ID: 37804922
[TBL] [Abstract][Full Text] [Related]
17. Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.
Liu X; Zhu X; Qi X; Meng X; Xu K
Int J Nanomedicine; 2021; 16():1037-1050. PubMed ID: 33603367
[TBL] [Abstract][Full Text] [Related]
18. TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib.
Hou C; Guo D; Yu X; Wang S; Liu T
Biomed Pharmacother; 2020 Jun; 126():109862. PubMed ID: 32120157
[TBL] [Abstract][Full Text] [Related]
19. Interventing mitochondrial PD-L1 suppressed IFN-γ-induced cancer stemness in hepatocellular carcinoma by sensitizing sorafenib-induced ferroptosis.
Li T; Huang HY; Qian B; Wang WH; Yuan Q; Zhang HY; He J; Ni KJ; Wang P; Zhao ZY; He JL; Fu SW; Xu L; Lin YC; Lin ZN
Free Radic Biol Med; 2024 Feb; 212():360-374. PubMed ID: 38171407
[TBL] [Abstract][Full Text] [Related]
20. Solasonine promotes ferroptosis of hepatoma carcinoma cells via glutathione peroxidase 4-induced destruction of the glutathione redox system.
Jin M; Shi C; Li T; Wu Y; Hu C; Huang G
Biomed Pharmacother; 2020 Sep; 129():110282. PubMed ID: 32531676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
